FDA Delays Decision On KalVista's Sebetralstat NDA For Hereditary Angioedema
(RTTNews) - KalVista Pharmaceuticals Inc. (KALV) announced Friday now that the U.S. Food and Drug Administration has notified the company that it will not meet the PDUFA goal date for the New Drug Application (NDA) for sebetralstat, the company's investigational oral on-demand t
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
